These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27890170)

  • 1. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention.
    Koutsianas C; Thomas K; Vassilopoulos D
    Rheum Dis Clin North Am; 2017 Feb; 43(1):133-149. PubMed ID: 27890170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatic diseases and hepatitis B virus coinfection.
    Felis-Giemza A; Olesińska M; Świerkocka K; Więsik-Szewczyk E; Haładyj E
    Rheumatol Int; 2015 Mar; 35(3):385-92. PubMed ID: 25549599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes.
    Vassilopoulos D
    Eur J Intern Med; 2011 Dec; 22(6):572-5. PubMed ID: 22075282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
    Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
    J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review].
    Gridneva GI; Belov BS; Aronova ES
    Ter Arkh; 2024 Jun; 96(5):523-530. PubMed ID: 38829815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatic manifestations of hepatitis.
    Vassilopoulos D; Manolakopoulos S
    Curr Opin Rheumatol; 2010 Jan; 22(1):91-6. PubMed ID: 19864952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
    Mori S; Fujiyama S
    World J Gastroenterol; 2015 Sep; 21(36):10274-89. PubMed ID: 26420955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
    Xuan D; Yu Y; Shao L; Wang J; Zhang W; Zou H
    Clin Rheumatol; 2014 Apr; 33(4):577-86. PubMed ID: 24343455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
    Su J; Long L; Zou K
    Clin Rheumatol; 2018 Dec; 37(12):3201-3214. PubMed ID: 29637482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians.
    Koffas A; Dolman GE; Kennedy PT
    Clin Med (Lond); 2018 Jun; 18(3):212-218. PubMed ID: 29858430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
    Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma.
    Zhou Q; Zhang Q; Wang K; Huang T; Deng S; Wang Y; Cheng C
    Pharmacol Res; 2022 Apr; 178():106181. PubMed ID: 35301112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
    Calabrese LH; Zein NN; Vassilopoulos D
    Ann Rheum Dis; 2006 Aug; 65(8):983-9. PubMed ID: 16627542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.
    Kato M; Atsumi T
    Rheumatol Int; 2016 May; 36(5):635-41. PubMed ID: 26573663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
    Atteya A; Ahmad A; Daghstani D; Mushtaq K; Yassin MA
    Cancer Control; 2020; 27(1):1073274820976594. PubMed ID: 33297765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.
    Smalls DJ; Kiger RE; Norris LB; Bennett CL; Love BL
    Pharmacotherapy; 2019 Dec; 39(12):1190-1203. PubMed ID: 31596963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
    Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
    Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy.
    Toka B; Eminler AT; Gönüllü E; Tozlu M; Uslan MI; Parlak E; Karabay O; Koksal AS
    Rheumatol Int; 2019 Dec; 39(12):2077-2085. PubMed ID: 31520109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.